Utama › Kanser Paru-paru › North Carolina › Durham
Kajian klinikal Kanser Paru-paru di Durham, NC
32 kajian untuk Kanser Paru-paru sedang mencari peserta di lokasi dalam dan sekitar Durham (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Mengambil pesertaFasa 3
- Duke University Medical Center, Durham
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Mengambil pesertaFasa 1/2
- Duke University, Durham
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- Durham VA Medical Center, Durham
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Mengambil pesertaFasa 3
- Durham VA Medical Center, Durham
- Duke University Medical Center, Durham
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Mengambil pesertaFasa 3
- Duke Cancer Center, Durham
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Mengambil pesertaFasa 3
- UNC Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill · 10 mi jauh
A Study of PHN-012 in Patients With Advanced Solid Tumors
Mengambil pesertaFasa 1
- PHN-012-001 Site, Durham
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Mengambil pesertaFasa 3
- Duke University Medical Center, Durham
Study of Trilaciclib and Lurbinectidin
Mengambil pesertaFasa 2
- Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill, Chapel Hill · 10 mi jauh
Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease
Mengambil pesertaFasa 2
- Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, Chapel Hill · 10 mi jauh
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Mengambil pesertaFasa 1/2
- Duke University School of Medicine, Durham
Effects of Infusion Timing on Treatment Response in Solid Tumors
Mengambil pesertaFasa 2
- University of North Carolina at Chapel Hill, Department of Radiation Oncology, Chapel Hill · 10 mi jauh
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Mengambil pesertaFasa 3
- Duke Cancer Institute, Durham
- University of North Carolina Medical Center, Chapel Hill · 10 mi jauh
The Vanguard Study: Testing a New Way to Screen for Cancer
Mengambil pesertaSukarelawan sihat dialu-alukan
- Durham VA Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauh
Health Education Approach to Lung Screening
Mengambil pesertaSukarelawan sihat dialu-alukan
- University of North Carolina-Chapel Hill, Carrboro · 11 mi jauh
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Mengambil pesertaFasa 3
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauh
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Mengambil pesertaFasa 1
- Xencor Investigative Site, Durham
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Mengambil pesertaFasa 1/2
- Duke University Medical Center, Durham
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi jauh
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
Mengambil peserta
- Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill · 10 mi jauh
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Mengambil pesertaFasa 2
- University of North Carolina, Chapel Hill · 10 mi jauh
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Mengambil pesertaFasa 1
- Research Site, Durham
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Mengambil pesertaFasa 2
- Durham VA Medical Center, Durham
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Mengambil pesertaFasa 1
- Duke Cancer Center, Durham
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Mengambil pesertaFasa 1/2
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi jauh
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Mengambil pesertaFasa 2/3
- Durham VA Medical Center, Durham
Telephone-based Physical Activity Coaching or Self Monitored Physical Activity to Improve Physical Function in Older Adults Who Are Undergoing Surgery for Lung Cancer and Their Caregivers
Mengambil pesertaSukarelawan sihat dialu-alukan
- Duke University, Durham
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
Mengambil peserta
- Durham VA Medical Center, Durham, NC, Durham
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Mengambil pesertaFasa 1
- Duke Cancer Institute, Durham
Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer
Mengambil pesertaFasa awal 1
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauh
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Mengambil pesertaKajian pemerhatian
- Massive Bio SYNERGY-AI site, Chapel Hill · 10 mi jauh
UNC Pleural Fluid Registry
Mengambil pesertaKajian pemerhatian
- UNC Lingeberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauh
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Mengambil pesertaFasa 2
- University of North Carolina, Chapel Hill · 10 mi jauh
Kajian Kanser Paru-paru di bandar lain
- Houston, TX78 kajian
- Boston, MA62 kajian
- New York City, NY60 kajian
- Los Angeles, CA45 kajian
- Washington, DC41 kajian
- Arlington, VA41 kajian
- Chicago, IL41 kajian
- Nashville, TN40 kajian
- Baltimore, MD40 kajian
- St. Louis, MO39 kajian
- Columbus, OH37 kajian
- Philadelphia, PA36 kajian
Kajian lain di Durham
- Kanser Payudara63 kajian
- Kanser (semua jenis)58 kajian
- Kanser Paru-paru Bukan Sel Kecil39 kajian
- Mieloma Pelbagai37 kajian
- Kanser Metastatik33 kajian
- Leukemia Mieloid Akut33 kajian
- Kanser Prostat32 kajian
- Kanser Kolorektal28 kajian
- Leukemia Limfositik Kronik27 kajian
- Kanser Ovari27 kajian
- Kegagalan Jantung26 kajian
- Kanser Pankreas24 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.